Exact Sciences

503 articles about Exact Sciences

• Exact Sciences schedules fourth quarter 2021 earnings call

  2/8/2022

  Exact Sciences Corp., a leader in advanced cancer diagnostics, announced that the company plans to release its fourth quarter 2021 financial results after the close of the U.S. financial markets on February 22, 2022.

• Exact Sciences to participate in February 2022 investor conferences

  2/1/2022

  Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

• Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

  1/18/2022

  Exact Sciences Corp. announced performance data for a second-generation Cologuard test showing overall sensitivity of 95.2% for colorectal cancer at specificity of 92.4% for negative samples confirmed by colonoscopy.

• Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

  1/10/2022

  Exact Sciences Corp. announced that the company expects to report revenue between $472 million and $475 million for the fourth quarter ended Dec. 31, 2021.

• Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

  1/10/2022

  Exact Sciences Corp. and OncXerna Therapeutics, Inc., a precision medicine company, announced they have entered an exclusive license agreement to bring OncXerna's Xerna TME Panel lab services to more U.S. patients.

• Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

  1/10/2022

  Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing.

• Exact Sciences to participate in J.P. Morgan Healthcare Conference - Jan 03, 2022

  1/3/2022

  Exact Sciences Corp. announced that company management will participate in the following virtual conference and invited investors to participate by webcast.

• 

  Clinical Catch-Up: November 29-December 3

  12/6/2021

  Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.

• New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients

  11/23/2021

  Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the importance of adverse pathology as a reliable and critical endpoint for risk-assessment in clinically low-risk prostate cancer patients.

• Phillips-Medisize and Exact Sciences Collaborate to Fight Colorectal Cancer

  11/3/2021

  Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic and MedTech devices, announces the successful collaboration with Exact Sciences, a global leader in cancer diagnostics, to advance early cancer detection.

• Exact Sciences announces third quarter 2021 results

  11/2/2021

  Exact Sciences Corp. announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020.

• Exact Sciences to participate in November 2021 investor conferences

  11/1/2021

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

• New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening

  10/25/2021

  Exact Sciences Corp. shared data from modeling analyses that demonstrate Cologuard, with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer compared to annual fecal immunochemical test, when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population.

• Exact Sciences schedules third quarter 2021 earnings call

  10/8/2021

  Exact Sciences Corp. announced that the company plans to release its third quarter 2021 financial results after the close of the U.S. financial markets on November 2, 2021.

• Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

  9/14/2021

  Exact Sciences Corp., a global leader in cancer diagnostics, announced that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project, a cooperative group founded by the National Cancer Institute.

• Exact Sciences to participate in September 2021 investor conferences

  9/1/2021

  Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

• Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan

  8/16/2021

  Exact Sciences Corp. announced that Japan's Ministry of Health, Labor and Welfare has approved the Oncotype DX Breast Recurrence Score® Program.

• Exact Sciences Announces Second Quarter 2021 Results

  7/28/2021

  Exact Sciences Corp. announced that the company generated revenue of $434.8 million for the second quarter ended June 30, 2021, compared to $268.9 million for the same period of 2020.

• Exact Sciences schedules second quarter 2021 earnings call

  7/8/2021

  Exact Sciences Corp. announced that the company plans to release its second quarter 2021 financial results after the close of the U.S. financial markets on July 28, 2021.

• Exact Sciences to participate in June 2021 investor conferences

  5/24/2021

  Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.